642 related articles for article (PubMed ID: 18618495)
21. [Radioembolization with (90)Y-microspheres for liver tumors].
Rodríguez-Fraile M; Iñarrairaegui M
Rev Esp Med Nucl Imagen Mol; 2015; 34(4):244-57. PubMed ID: 25911062
[No Abstract] [Full Text] [Related]
22. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up.
Andrews JC; Walker SC; Ackermann RJ; Cotton LA; Ensminger WD; Shapiro B
J Nucl Med; 1994 Oct; 35(10):1637-44. PubMed ID: 7931662
[TBL] [Abstract][Full Text] [Related]
23. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.
Bester L; Meteling B; Pocock N; Pavlakis N; Chua TC; Saxena A; Morris DL
J Vasc Interv Radiol; 2012 Jan; 23(1):96-105. PubMed ID: 22079516
[TBL] [Abstract][Full Text] [Related]
24. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer.
Coldwell DM; Kennedy AS; Nutting CW
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):800-4. PubMed ID: 17524567
[TBL] [Abstract][Full Text] [Related]
25. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
Flamen P; Vanderlinden B; Delatte P; Ghanem G; Ameye L; Van Den Eynde M; Hendlisz A
Phys Med Biol; 2008 Nov; 53(22):6591-603. PubMed ID: 18978442
[TBL] [Abstract][Full Text] [Related]
26. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
Hendlisz A; Van den Eynde M; Peeters M; Maleux G; Lambert B; Vannoote J; De Keukeleire K; Verslype C; Defreyne L; Van Cutsem E; Delatte P; Delaunoit T; Personeni N; Paesmans M; Van Laethem JL; Flamen P
J Clin Oncol; 2010 Aug; 28(23):3687-94. PubMed ID: 20567019
[TBL] [Abstract][Full Text] [Related]
27. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases.
Saxena A; Chua TC; Bester L; Kokandi A; Morris DL
Ann Surg; 2010 May; 251(5):910-6. PubMed ID: 20395859
[TBL] [Abstract][Full Text] [Related]
28. Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.
van den Hoven AF; Rosenbaum CE; Elias SG; de Jong HW; Koopman M; Verkooijen HM; Alavi A; van den Bosch MA; Lam MG
J Nucl Med; 2016 Jul; 57(7):1014-9. PubMed ID: 26912436
[TBL] [Abstract][Full Text] [Related]
29. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
[TBL] [Abstract][Full Text] [Related]
30. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres.
Lau WY; Kennedy AS; Kim YH; Lai HK; Lee RC; Leung TW; Liu CS; Salem R; Sangro B; Shuter B; Wang SC
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):401-7. PubMed ID: 20950954
[TBL] [Abstract][Full Text] [Related]
31. Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT.
Chansanti O; Jahangiri Y; Matsui Y; Adachi A; Geeratikun Y; Kaufman JA; Kolbeck KJ; Stevens JS; Farsad K
J Vasc Interv Radiol; 2017 Nov; 28(11):1528-1535. PubMed ID: 28888827
[TBL] [Abstract][Full Text] [Related]
32. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results.
Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
J Cancer Res Clin Oncol; 2017 Mar; 143(3):481-489. PubMed ID: 27826686
[TBL] [Abstract][Full Text] [Related]
33. Towards new response criteria in neuroendocrine tumors: which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases?
Ceelen F; Theisen D; de Albéniz XG; Auernhammer CJ; Haug AR; D'Anastasi M; Paprottka PM; Rist C; Reiser MF; Sommer WH
J Magn Reson Imaging; 2015 Feb; 41(2):361-8. PubMed ID: 24446275
[TBL] [Abstract][Full Text] [Related]
34. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors.
Pöpperl G; Helmberger T; Münzing W; Schmid R; Jacobs TF; Tatsch K
Cancer Biother Radiopharm; 2005 Apr; 20(2):200-8. PubMed ID: 15869456
[TBL] [Abstract][Full Text] [Related]
35. Radioembolization with
Braat AJAT; Kappadath SC; Ahmadzadehfar H; Stothers CL; Frilling A; Deroose CM; Flamen P; Brown DB; Sze DY; Mahvash A; Lam MGEH
Cardiovasc Intervent Radiol; 2019 Mar; 42(3):413-425. PubMed ID: 30603975
[TBL] [Abstract][Full Text] [Related]
36. Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.
Burgmans MC; Kao YH; Irani FG; Dames EL; Teo TK; Goh AS; Chow PK; Tay KH; Lo RH
J Vasc Interv Radiol; 2012 Oct; 23(10):1294-301. PubMed ID: 22922039
[TBL] [Abstract][Full Text] [Related]
37. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients.
Saxena A; Meteling B; Kapoor J; Golani S; Morris DL; Bester L
Ann Surg Oncol; 2015 Mar; 22(3):794-802. PubMed ID: 25323474
[TBL] [Abstract][Full Text] [Related]
38. Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response.
Lacin S; Oz I; Ozkan E; Kucuk O; Bilgic S
Cancer Biother Radiopharm; 2011 Oct; 26(5):631-7. PubMed ID: 21950557
[TBL] [Abstract][Full Text] [Related]
39. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
Kennedy AS; Dezarn WA; McNeillie P; Coldwell D; Nutting C; Carter D; Murthy R; Rose S; Warner RR; Liu D; Palmedo H; Overton C; Jones B; Salem R
Am J Clin Oncol; 2008 Jun; 31(3):271-9. PubMed ID: 18525307
[TBL] [Abstract][Full Text] [Related]
40. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
Kousik V; Promila P; Verma R; Gupta A
Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
